Prostatype Genomics Valuation
| PROGEN Stock | SEK 7.50 0.15 1.96% |
At this time, the company appears to be overvalued. Prostatype Genomics holds a recent Real Value of kr7.2 per share. The prevailing price of the company is kr7.5. Our model determines the value of Prostatype Genomics from analyzing the company fundamentals such as Current Valuation of 20.62 M, return on equity of -0.7, and Shares Owned By Insiders of 1.00 % as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Prostatype Genomics' price fluctuation is unstable at this time. Calculation of the real value of Prostatype Genomics is based on 3 months time horizon. Increasing Prostatype Genomics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Prostatype Genomics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Prostatype Stock. However, Prostatype Genomics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 7.5 | Real 7.2 | Hype 7.5 | Naive 8.56 |
The real value of Prostatype Stock, also known as its intrinsic value, is the underlying worth of Prostatype Genomics Company, which is reflected in its stock price. It is based on Prostatype Genomics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Prostatype Genomics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Prostatype Genomics AB helps investors to forecast how Prostatype stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Prostatype Genomics more accurately as focusing exclusively on Prostatype Genomics' fundamentals will not take into account other important factors: Prostatype Genomics Total Value Analysis
Prostatype Genomics AB is at this time estimated to have takeover price of 20.62 M with market capitalization of 42.29 M, debt of 866.67 K, and cash on hands of 7.66 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Prostatype Genomics fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
20.62 M | 42.29 M | 866.67 K | 7.66 M |
Prostatype Genomics Investor Information
About 13.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.14. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Prostatype Genomics recorded a loss per share of 1.22. The entity had not issued any dividends in recent years. The firm had 1000:1 split on the 18th of August 2024. Based on the key indicators related to Prostatype Genomics' liquidity, profitability, solvency, and operating efficiency, Prostatype Genomics AB is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.Prostatype Genomics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Prostatype Genomics has an asset utilization ratio of 0.0249 percent. This suggests that the Company is making kr2.49E-4 for each dollar of assets. An increasing asset utilization means that Prostatype Genomics AB is more efficient with each dollar of assets it utilizes for everyday operations.Prostatype Genomics Ownership Allocation
Prostatype Genomics owns a total of 22.86 Million outstanding shares. Roughly 85.53 pct. of Prostatype Genomics outstanding shares are held by general public with 1.0 % owned by insiders and only 13.47 (%) by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.Prostatype Genomics Profitability Analysis
The company reported the revenue of 10 K. Net Loss for the year was (15.63 M) with loss before overhead, payroll, taxes, and interest of (5.98 M).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Prostatype Genomics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Prostatype Genomics and how it compares across the competition.
About Prostatype Genomics Valuation
The stock valuation mechanism determines Prostatype Genomics' current worth on a weekly basis. Our valuation model uses a comparative analysis of Prostatype Genomics. We calculate exposure to Prostatype Genomics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Prostatype Genomics's related companies.Prostatype Genomics AB manufactures, markets, and sells the prognostic gene tests. The company was founded in 2007 and is based in Solna, Sweden. Prostatype Genomics is traded on Stockholm Stock Exchange in Sweden.
8 Steps to conduct Prostatype Genomics' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Prostatype Genomics' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Prostatype Genomics' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Prostatype Genomics' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Prostatype Genomics' revenue streams: Identify Prostatype Genomics' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Prostatype Genomics' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Prostatype Genomics' growth potential: Evaluate Prostatype Genomics' management, business model, and growth potential.
- Determine Prostatype Genomics' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Prostatype Genomics' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for Prostatype Stock analysis
When running Prostatype Genomics' price analysis, check to measure Prostatype Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Prostatype Genomics is operating at the current time. Most of Prostatype Genomics' value examination focuses on studying past and present price action to predict the probability of Prostatype Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Prostatype Genomics' price. Additionally, you may evaluate how the addition of Prostatype Genomics to your portfolios can decrease your overall portfolio volatility.
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |